Pharvaris announced the appointment of David Nassif as CFO, effective April 15. In this role, he will be responsible for refining and implementing Pharvaris’ corporate financial strategy and activities including financial reporting and operations. Nassif joins Pharvaris with more than 30 years of experience in financial management, strategic planning, mergers and acquisitions, investor relations, legal, and capital allocation, having held multiple executive financial management roles in development-stage, commercial-stage, public and private companies. Nassif serves as CEO, CFO, and board member at Sio Gene Therapies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PHVS:
- Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
- Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
- Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
- Pharvaris initiates RAPIDe-3, the Phase 3 clinical trial
- Pharvaris files to sell 5.55M ordinary shares for holders